Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
- Creators
- Cazzaniga M. E.
- Verusio C.
- Ciccarese M.
- Fumagalli A.
- Sartori D.
- Valerio M. R.
- Airoldi M.
- Moretti G.
- Ficorella C.
- Gianni L.
- Michelotti A.
- Zambelli A.
- Febbraro A.
- Generali D.
- Pistelli M.
- Garrone O.
- Musolino A.
- Vici P.
- Maur M.
- Mentuccia L.
- La Verde N.
- Bianchi G. V.
- Artale S.
- Blasi L.
- De Laurentiis M.
- Atzori F.
- Turletti A.
- Porpiglia M.
- Santini D.
- Fabi A.
- Gebbia V.
- Schirone A.
- Palumbo R.
- Ferzi A.
- Frassoldati A.
- Scavelli C.
- Clivio L.
- Giordano M.
- Donadio M.
- Biganzoli L.
- Del Mastro L.
- Bisagni G.
- Livi L.
- Natoli C.
- Montemurro F.
- Riccardi F.
- Romagnoli E.
- Marchetti P.
- Torri V.
- Pronzato P.
- Mustacchi G.
- Others:
- Cazzaniga, M. E.
- Verusio, C.
- Ciccarese, M.
- Fumagalli, A.
- Sartori, D.
- Valerio, M. R.
- Airoldi, M.
- Moretti, G.
- Ficorella, C.
- Vernazza, Gianni
- Michelotti, A.
- Zambelli, A.
- Febbraro, A.
- Generali, D.
- Pistelli, M.
- Garrone, O.
- Musolino, A.
- Vici, P.
- Maur, M.
- Mentuccia, L.
- La Verde, N.
- Bianchi, G. V.
- Artale, S.
- Blasi, L.
- De Laurentiis, M.
- Atzori, F.
- Turletti, A.
- Porpiglia, M.
- Santini, D.
- Fabi, A.
- Gebbia, V.
- Schirone, A.
- Palumbo, R.
- Ferzi, A.
- Frassoldati, A.
- Scavelli, C.
- Clivio, L.
- Giordano, M.
- Donadio, M.
- Biganzoli, L.
- Del Mastro, L.
- Bisagni, G.
- Livi, L.
- Natoli, C.
- Montemurro, F.
- Riccardi, F.
- Romagnoli, E.
- Marchetti, P.
- Torri, V.
- Pronzato, P.
- Mustacchi, G.
Description
Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.
Additional details
- URL
- https://hdl.handle.net/11567/1019632
- URN
- urn:oai:iris.unige.it:11567/1019632
- Origin repository
- UNIGE